CLINICAL ROLE -
Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.
Study Examining Glofitamab With GemOX in Patients With R/R DLBCL Meets Primary Endpoint
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Insights, Future Considerations in FLT3 Inhibitors Following Allo-HCT in Patients With AML
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Study Suggests Patients With Low-Risk CLL May Stop Specialized Follow-Up Visits
Addressing the Challenges of Implementing Bispecific Antibodies in Health Care Centers